This is in pursuance to the announcement made in the Union Budget for the year 2024-25 exempting these three anti-cancer medicines from customs duty
India has been declared ‘functional’ against all the core regulatory functions of the WHO Global Benchmarking Tool Version VI
Global survey reveals top workforce concerns, evolving strategic priorities, and key technology investment areas for life sciences manufacturers
The raised capital enables Medix Biochemica to continue execution of inorganic growth initiatives
The new bioeconomy policy rolled out by the Modi government is set to place India as a global leader in the years to come
Honeywell Quality Management Review helps manufacturers boost efficiency and quality compliance
Stringent regulatory environments can make OEMs reluctant to change processes and materials for approved medical devices
Capital expenditure expected to moderate to Rs. 5.6 billion in FY2025 from an estimated Rs. 7.6 billion in FY2024
He advocated for a "PPP + PPP" collaboration, urging the public and private sectors within India to partner with their counterparts in other countries
The Central government’s decision to exempt three more cancer medicines from customs duty is a commendable step towards making cancer drugs more affordable
Subscribe To Our Newsletter & Stay Updated
